WeTrials
Recruiting

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

What is this study?

This study tests whether personalized treatments using targeted drugs called antibody-drug conjugates can help patients with advanced solid tumors. It looks at specific proteins on cancer cells to match each patient with the medication that is most likely to attack their specific tumor.

Who can participate?

You may be able to join if you have an advanced or metastatic solid tumor that has not responded well to standard treatments or has no standard treatment options left. Your tumor will be tested for specific proteins like Trop-2, nectin-4, or HER2 to see which study medicine is right for you.

What will happen?

You will undergo tissue and blood tests, imaging scans like CT or MRI, and heart function checks to see if you qualify and to monitor your health. Depending on your test results, you will receive one of the targeted study medications designed to home in on your cancer cells.

Where and when?

This study is currently recruiting participants at locations in California, United States. Your care team will guide you through the exact steps and visit schedules at your nearest study site.

Key Points
  • 1Tests personalized treatments matched to your tumor's specific protein profile.
  • 2Uses targeted medications designed to deliver cancer-killing drugs directly to tumor cells.
  • 3Currently recruiting participants with advanced solid tumors at select locations in California.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.